Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2020 | APR-246 combination treatments in TP53-mutant R/R NHLs

Meghan Thompson • 8 Dec 2020
ASH 2020
Chronic Lymphocytic Leukemia Leukemia Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Antibodies Eprenetapopt Ibrutinib Rituximab Venetoclax

Meghan Thompson, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses an upcoming Phase 1 study (NCT04419389) aiming to evaluate the efficacy and safety of APR-246 in combination with ibrutinib or a venetoclax-based therapy in patients with TP53-mutant relapsed/refractory (R/R) non-Hodgkin lymphomas (NHLs), including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Enrollment for this trial is ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Curio Science

More from Meghan Thompson

Advice for young investigators entering the CLL space and key areas of interest
1:43
Advice for young investigators entering the CLL space and key areas of interest
Meghan Thompson • 4 Sep 2025
An update on BTK-targeting therapies in NHL & CLL: combinations, BTK degraders, and ongoing trials
14:48
An update on BTK-targeting therapies in NHL & CLL: combinations, BTK degraders, and ongoing trials
Meghan Thompson • 28 Sep 2025
Novel agents showing promise for the treatment of double-refractory CLL
1:18
Novel agents showing promise for the treatment of double-refractory CLL
Meghan Thompson • 5 Sep 2025
How to approach sequencing in CLL amid expanding treatment options
1:22
How to approach sequencing in CLL amid expanding treatment options
Meghan Thompson • 5 Sep 2025

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Meghan Thompson • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Meghan Thompson • 6 Dec 2025
Beat AML abstracts at ASH 2025: ficlatuzumab sub-study, PRISM score, and the impact of co-mutations
3:16
Beat AML abstracts at ASH 2025: ficlatuzumab sub-study, PRISM score, and the impact of co-mutations
Meghan Thompson • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Meghan Thompson • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals